drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Autologous gene-modified T lymphocytes expressing a chimeric antigen receptor targeting Fc receptor–like 5 (FcRL5/CD307e) on multiple myeloma cells to mediate antigen-directed cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor that binds FcRL5 (CD307e) on multiple myeloma cells; CAR engagement triggers CD3z/costimulatory signaling, leading to T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of FcRL5-positive plasma cells.
drug_name
anti-FcRL5 CAR-T cells
nct_id_drug_ref
NCT06196255